In 2011, the FDA had made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for T1D, and announced it was preparing draft guidelines. JDRF launched a campaign to influence those guidelines to be lenient. After the first closed loop device was approved in 2016, JDRF lobbied insurance companies to cover it. The campaign also put resources into educating people with diabetes on how to navigate health insurance in the United States, and into lobbying Congress to continue funding diabetes research through the NIH.